null
100% Quality Guarantee
PhD-Level Technical Support
Key Features

FITC Anti-Mouse CD274/PD-L1 Antibody [10F.9G2] (AGEL2260)

SKU AGEL2260
Product Type Antibody
Antibody Type Monoclonal Antibody
Applications FCM
Reactivity Mouse
Host Species Rat
Isotype Rat IgG2b, κ
Clone 10F.9G2
Conjugation FITC
€57 - €144
Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

FITC Anti-Mouse CD274/PD-L1 Antibody [10F.9G2]

The FITC Anti-Mouse CD274 (PD-L1) Antibody (10F.9G2) (AGEL2260) offered by AssayGenie is a cutting-edge tool designed for researchers studying immune checkpoint proteins in the context of immunotherapy and cancer research. This antibody specifically targets the PD-L1 protein, a key regulator of immune responses, particularly in the suppression of T cell activity.By utilizing this antibody, researchers can effectively detect and analyze PD-L1 expression in mouse samples, enabling detailed investigation into its role in immune evasion mechanisms within the tumor microenvironment. The high specificity and sensitivity of this antibody make it a valuable asset for understanding the interplay between PD-L1 and immune cells, providing crucial insights for the development of novel immunotherapies targeting this pathway.

PD-L1 has emerged as a critical biomarker in cancer immunotherapy, with its overexpression associated with immune evasion and resistance to treatment. By elucidating the intricate mechanisms underlying PD-L1 regulation and function, researchers can pave the way for innovative strategies to enhance the efficacy of immune checkpoint blockade therapies and combat tumor immune evasion mechanisms.In summary, the FITC Anti-Mouse CD274 (PD-L1) Antibody (10F.9G2) (AGEL2260) from AssayGenie offers a potent and reliable tool for investigating the role of PD-L1 in immune modulation and cancer progression, making it an essential resource for researchers dedicated to advancing our understanding of immune checkpoint pathways.

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose